MPL: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of MPL. The page also collects GeneMedi's different modalities and formats products for MPL in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the MPL target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated. [provided by RefSeq, Jul 2008]
| Target ID | GM-T16156 |
| Target Name | MPL |
| Gene ID | 4352,17480,366455,610801,101097002,528492,100066544 |
| Gene Symbol and Synonyms | C-MPL,CD110,hlb219,MPL,MPLV,THCYT2,THPOR,TPO-R,TPOR |
| Uniprot Accession | P40238 |
| Uniprot Entry Name | TPOR_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, INN Index |
| Disease | Cancer |
| Gene Ensembl | ENSG00000117400 |
| Target Classification | Cytokine receptor, Tumor-associated antigen (TAA) |
Pre-made MPL-specific INN-index biosimilar (antibody&conjugates)
Anti-MPL therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
| Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Detail |
| GMP-Bios-INN-977 | Pre-Made Romiplostim Biosimilar, Fusion Protein targeting MPL fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting C-MPL/CD110/MPLV/THCYT2/THPOR/TPOR | romiplostim | MPL | Fusion Protein | Detail |
Click to check more INN-indexed antibody & protein biosimilar
Pre-made anti-MPL inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-MPL benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-MPL mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Antibody Name | Species | Format | Classified by tag | Detail |
| Anti-MPL monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
Multi-species TPOR/ MPL/ C-MPL VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MPL VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
| Products Name | Species | Expression Platform | Detail |
| MPL VLP (virus-like particle) | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Products Developing |
Pre-made MPL viral vector in GM Promise-ORFTM
| Cat No. | Products name | NM ID | Species | Type | Detail |
| pGMLP005099 | human MPL Lentivirus plasmid | NM_005373 | Human | Lentivirus plasmid | Detail |
| vGMLP005099 | human MPL Lentivirus particle | NM_005373 | Human | Lentivirus particle | Detail |
About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.
Facebook
LinkedIn
Twitter
